If you’re wanting to build a strong portfolio, then having a few blue chips in there could be a good starting point.
But which blue chips should you buy? Two highly rated blue chip shares are listed below. Here’s why they could be in the buy zone right now:
Goodman Group (ASX: GMG)
The first blue chip ASX 200 share to look at is Goodman Group. It is a leading integrated commercial and industrial property company with a portfolio of warehouses, large scale logistics facilities, and business and office parks.
It has been experiencing very strong demand for these properties in recent years, which is underpinning solid earnings and distribution growth.
Goodman’s CEO, Greg Goodman, recently commented: “The results of the deliberate positioning of our portfolio over the last decade to adapt to and leverage the changes in the digital economy, are now being realised. Customer demand for high-quality properties close to consumers has never been greater.”
But it gets better. Goodman has $12.7 billion of development work in progress, which is expected to underpin further growth over the coming years.
Citi is a fan of Goodman. It currently has a buy rating and $28.00 price target on the company’s shares. The broker believes that Goodman’s earnings per share guidance for FY 2022 is conservative.
ResMed Inc. (ASX: RMD)
Another blue chip ASX 200 share to look at is ResMed. It is a sleep treatment-focused medical device company with a portfolio of industry-leading products that are improving the lives of sufferers of conditions such as sleep apnoea.
The good news is that this is a huge market with just an estimated one fifth of sufferers currently diagnosed. This gives ResMed a long runway for growth in the future.
For example, ResMed’s CEO, Mick Farrell, recently reaffirmed his expectation for the company to improve a quarter of a billion lives by 2025.
He commented: “Despite constantly evolving market dynamics, we remain focused on our goal to improve 250 million lives in the year 2025; supporting patients with the sleep apnea therapy, respiratory care therapy, and digital health solutions they need as we deliver value for all of our customers.”
The team at Morgans is very positive on ResMed. It has an add rating and $40.46 price target on the company’s shares. The broker believes ResMed is “well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.”
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of January 12th 2022
- Morgans names 4 more of the best ASX shares to buy in February
- 3 fantastic ASX shares to buy this month
- Leading brokers name 3 ASX shares to buy today
- ASX 200 (ASX:XJO) midday update: Ansell crushed, ResMed upgraded
- Broker upgrade sends ResMed (ASX:RMD) share price charging higher
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/KubTYjA